Generic Medicine Info
Indications and Dosage
Pituitary desensitisation before ovulation induction with gonadotrophins
Adult: 400 mcg bid, given as 1 spray to each nostril in the morning and 1 spray to each nostril in the evening, starting either on the early follicular phase (day 2) or midluteal phase (day 21) of menstrual cycle, continued until down-regulation is achieved. Max treatment duration: 12 wk.

Adult: 200 mcg bid, given as 1 spray (200 mcg) in 1 nostril in the morning and 1 spray in the other nostril in the evening, starting on days 2-4 of menstrual cycle. Dose may be doubled after 2 mth if symptoms persist. Max treatment duration: 6 mth.

Central precocious puberty
Child: 800 mcg bid, given as 2 sprays (400 mcg) into each nostril in the morning and 2 sprays into each nostril in the evening. Dose may be increased up to 600 mcg tid, if necessary depending on response.
Undiagnosed abnormal vag bleeding. Pregnancy and lactation.
Special Precautions
Patient w/ pituitary adenoma, polycystic ovarian disease, psychiatric comorbidities, risk factors for BMD, intercurrent rhinitis; history of seizures, cerebrovascular disorders, CNS anomalies or tumours. Childn.
Adverse Reactions
Significant: Ovarian cysts, risk of cystic enlargement, decreased BMD, pituitary apoplexy (e.g. sudden headache, CV collapse, vomiting, visual/mental status change); psychiatric events (e.g. emotional lability, irritability, aggression, depression), seizures, convulsions, vag bleeding, breast enlargement.
Nervous: Insomnia, paraesthesia.
CV: Oedema, HTN, hypotension.
Resp: Rhinitis, nasal mucosal irritation.
Genitourinary: Vulvovaginal dryness, vag discharge, uterine haemorrhage, ovarian hyperstimulation syndrome.
Endocrine: Hot flushes, variable libido, artificial menopause, hypertriglyceridaemia, breast atrophy, hypercholesterolaemia, wt gain/loss, oestrogen deficiency.
Haematologic: WBC decrease, eosinophilia.
Musculoskeletal: Myalgia, arthralgia.
Dermatologic: Acne vulgaris, hypertrichosis, body odor, seborrhoea, hirsutism, alopecia.
Immunologic: Hypersensitivity reactions (e.g. chest pain, urticaria, pruritus, dyspnoea, rash).
Others: Hyperphosphataemia, hypocalcaemia.
Monitoring Parameters
Monitor BMD (prior to therapy and before retreatment), FSH and LH blood levels, bone age measurement, development or worsening of psychiatric symptoms, menstruation, vag bleeding/spotting.
Drug Interactions
May enhance the effect of corifollitropin alfa.
Lab Interference
May give misleading result in the diagnostic test for pituitary gonadotropic and gonadal functions up to 4-8 wk after treatment discontinuation.
Description: Nafarelin is a gonadorelin analogue. It produces an initial phase of stimulation followed by down-regulation of gonadotrophin-releasing hormone receptors, thus reducing the release of FSH and LH, leading to inhibition of androgen and oestrogen production.
Absorption: Rapidly absorbed intranasally. Bioavailability: Approx 3%. Time to peak plasma concentration: W/in 20 min.
Distribution: Plasma protein binding: Approx 80%, mainly to albumin.
Metabolism: Metabolised by peptidases to form metabolites.
Excretion: Via urine (44-55%, approx 3% as unchanged drug); faeces (19-44%). Elimination half-life: Approx 3 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Nafarelin, CID=25077405, (accessed on Jan. 22, 2020)

Store below 25°C. Protect from light. Do not freeze.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CA02 - nafarelin ; Belongs to the class of gonadotropin-releasing hormones. Used in hypothalamic hormone preparations.
Anon. Nafarelin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/10/2017.

Buckingham R (ed). Nafarelin Acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/10/2017.

Joint Formulary Committee. Nafarelin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 05/10/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Nafarelin Acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 05/10/2017.

Synarel Spray Metered (G.D. Searle LLC Division of Pfizer Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/10/2017.

Disclaimer: This information is independently developed by MIMS based on Nafarelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in